Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation

Rie Yamazaki, Hideki Nakasone, Yukie Tanaka, Miki Sato, Kiriko Terasako, Hidenori Wada, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Masahiro Ashizawa, Tomohito Machishima, Shun ichi Kimura, Misato Kikuchi, Shinya Okuda, Shinichi Kako, Junya Kanda, Aki Tanihara, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Varicella-zoster virus (VZV) reactivation is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Although previous studies have revealed that cellular immunity is important for suppressing reactivation, the role of humoral immunity against VZV has been poorly evaluated. We analyzed inherited polymorphisms in the immunoglobulin G (IgG) heavy chain constant regions of 50 HSCT recipient-donor pairs to distinguish donor-derived and recipient-derived antibodies. Twelve pairs were informative regarding the origin of IgG, since either the donors (n= 3) or recipients (n= 9) were homozygous null for the IgG1m(f) allotype. In these 9 homozygous-null recipients, allotype-specific IgG against VZV were measured by enzyme-linked immunosorbent assay and compared with measles-IgG. All 9 homozygous-null recipients were monitored for more than 1 year after HSCT, with (n= 4, localized zoster) or without (n= 5) clinical VZV disease. In 3 patients with VZV disease, donor-derived IgG against VZV was elevated between 500 to 700 days after HSCT after the episode of VZV disease. In 1 patient who suffered from VZV disease just before HSCT, donor-derived VZV IgG was elevated within 3 months after HSCT. On the other hand, 2 patients who received reduced-intensity conditioning (RIC) transplantation from an IgG1m(f) null donor maintained recipient-derived IgG against VZV for more than 1 year, whereas it was decreased within 3 months in 1 recipient who received conventional conditioning. In conclusion, the production of anti-VZV IgG by recipient plasma cells persists long after RIC. In patients without symptomatic VZV reactivation, donor-derived anti-VZV IgG did not reach titers comparable to those measured in healthy virus carriers.

Original languageEnglish
Pages (from-to)1013-1020
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number7
DOIs
Publication statusPublished - 2013 Jul 1
Externally publishedYes

Fingerprint

Human Herpesvirus 3
Stem Cell Transplantation
Immunoglobulin G
Hematopoietic Stem Cell Transplantation
Tissue Donors
Virus Diseases
Transplantation Conditioning
Immunoglobulin Heavy Chains
Herpes Zoster
Measles
Humoral Immunity
Plasma Cells
Cellular Immunity

Keywords

  • Allogeneic stem cell transplantation
  • Humoral immunity
  • Immunoglobulin G allotype
  • Varicella-Zoster virus

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation. / Yamazaki, Rie; Nakasone, Hideki; Tanaka, Yukie; Sato, Miki; Terasako, Kiriko; Wada, Hidenori; Ishihara, Yuko; Kawamura, Koji; Sakamoto, Kana; Ashizawa, Masahiro; Machishima, Tomohito; Kimura, Shun ichi; Kikuchi, Misato; Okuda, Shinya; Kako, Shinichi; Kanda, Junya; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 7, 01.07.2013, p. 1013-1020.

Research output: Contribution to journalArticle

Yamazaki, R, Nakasone, H, Tanaka, Y, Sato, M, Terasako, K, Wada, H, Ishihara, Y, Kawamura, K, Sakamoto, K, Ashizawa, M, Machishima, T, Kimura, SI, Kikuchi, M, Okuda, S, Kako, S, Kanda, J, Tanihara, A, Nishida, J & Kanda, Y 2013, 'Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 19, no. 7, pp. 1013-1020. https://doi.org/10.1016/j.bbmt.2013.04.007
Yamazaki, Rie ; Nakasone, Hideki ; Tanaka, Yukie ; Sato, Miki ; Terasako, Kiriko ; Wada, Hidenori ; Ishihara, Yuko ; Kawamura, Koji ; Sakamoto, Kana ; Ashizawa, Masahiro ; Machishima, Tomohito ; Kimura, Shun ichi ; Kikuchi, Misato ; Okuda, Shinya ; Kako, Shinichi ; Kanda, Junya ; Tanihara, Aki ; Nishida, Junji ; Kanda, Yoshinobu. / Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 7. pp. 1013-1020.
@article{54bb3cde8a9f4e5c9939767758ad4b8d,
title = "Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation",
abstract = "Varicella-zoster virus (VZV) reactivation is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Although previous studies have revealed that cellular immunity is important for suppressing reactivation, the role of humoral immunity against VZV has been poorly evaluated. We analyzed inherited polymorphisms in the immunoglobulin G (IgG) heavy chain constant regions of 50 HSCT recipient-donor pairs to distinguish donor-derived and recipient-derived antibodies. Twelve pairs were informative regarding the origin of IgG, since either the donors (n= 3) or recipients (n= 9) were homozygous null for the IgG1m(f) allotype. In these 9 homozygous-null recipients, allotype-specific IgG against VZV were measured by enzyme-linked immunosorbent assay and compared with measles-IgG. All 9 homozygous-null recipients were monitored for more than 1 year after HSCT, with (n= 4, localized zoster) or without (n= 5) clinical VZV disease. In 3 patients with VZV disease, donor-derived IgG against VZV was elevated between 500 to 700 days after HSCT after the episode of VZV disease. In 1 patient who suffered from VZV disease just before HSCT, donor-derived VZV IgG was elevated within 3 months after HSCT. On the other hand, 2 patients who received reduced-intensity conditioning (RIC) transplantation from an IgG1m(f) null donor maintained recipient-derived IgG against VZV for more than 1 year, whereas it was decreased within 3 months in 1 recipient who received conventional conditioning. In conclusion, the production of anti-VZV IgG by recipient plasma cells persists long after RIC. In patients without symptomatic VZV reactivation, donor-derived anti-VZV IgG did not reach titers comparable to those measured in healthy virus carriers.",
keywords = "Allogeneic stem cell transplantation, Humoral immunity, Immunoglobulin G allotype, Varicella-Zoster virus",
author = "Rie Yamazaki and Hideki Nakasone and Yukie Tanaka and Miki Sato and Kiriko Terasako and Hidenori Wada and Yuko Ishihara and Koji Kawamura and Kana Sakamoto and Masahiro Ashizawa and Tomohito Machishima and Kimura, {Shun ichi} and Misato Kikuchi and Shinya Okuda and Shinichi Kako and Junya Kanda and Aki Tanihara and Junji Nishida and Yoshinobu Kanda",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.bbmt.2013.04.007",
language = "English",
volume = "19",
pages = "1013--1020",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Allotype Analysis to Distinguish the Origin of Varicella-Zoster Virus Immunoglobulin G after Allogeneic Stem Cell Transplantation

AU - Yamazaki, Rie

AU - Nakasone, Hideki

AU - Tanaka, Yukie

AU - Sato, Miki

AU - Terasako, Kiriko

AU - Wada, Hidenori

AU - Ishihara, Yuko

AU - Kawamura, Koji

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Machishima, Tomohito

AU - Kimura, Shun ichi

AU - Kikuchi, Misato

AU - Okuda, Shinya

AU - Kako, Shinichi

AU - Kanda, Junya

AU - Tanihara, Aki

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Varicella-zoster virus (VZV) reactivation is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Although previous studies have revealed that cellular immunity is important for suppressing reactivation, the role of humoral immunity against VZV has been poorly evaluated. We analyzed inherited polymorphisms in the immunoglobulin G (IgG) heavy chain constant regions of 50 HSCT recipient-donor pairs to distinguish donor-derived and recipient-derived antibodies. Twelve pairs were informative regarding the origin of IgG, since either the donors (n= 3) or recipients (n= 9) were homozygous null for the IgG1m(f) allotype. In these 9 homozygous-null recipients, allotype-specific IgG against VZV were measured by enzyme-linked immunosorbent assay and compared with measles-IgG. All 9 homozygous-null recipients were monitored for more than 1 year after HSCT, with (n= 4, localized zoster) or without (n= 5) clinical VZV disease. In 3 patients with VZV disease, donor-derived IgG against VZV was elevated between 500 to 700 days after HSCT after the episode of VZV disease. In 1 patient who suffered from VZV disease just before HSCT, donor-derived VZV IgG was elevated within 3 months after HSCT. On the other hand, 2 patients who received reduced-intensity conditioning (RIC) transplantation from an IgG1m(f) null donor maintained recipient-derived IgG against VZV for more than 1 year, whereas it was decreased within 3 months in 1 recipient who received conventional conditioning. In conclusion, the production of anti-VZV IgG by recipient plasma cells persists long after RIC. In patients without symptomatic VZV reactivation, donor-derived anti-VZV IgG did not reach titers comparable to those measured in healthy virus carriers.

AB - Varicella-zoster virus (VZV) reactivation is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Although previous studies have revealed that cellular immunity is important for suppressing reactivation, the role of humoral immunity against VZV has been poorly evaluated. We analyzed inherited polymorphisms in the immunoglobulin G (IgG) heavy chain constant regions of 50 HSCT recipient-donor pairs to distinguish donor-derived and recipient-derived antibodies. Twelve pairs were informative regarding the origin of IgG, since either the donors (n= 3) or recipients (n= 9) were homozygous null for the IgG1m(f) allotype. In these 9 homozygous-null recipients, allotype-specific IgG against VZV were measured by enzyme-linked immunosorbent assay and compared with measles-IgG. All 9 homozygous-null recipients were monitored for more than 1 year after HSCT, with (n= 4, localized zoster) or without (n= 5) clinical VZV disease. In 3 patients with VZV disease, donor-derived IgG against VZV was elevated between 500 to 700 days after HSCT after the episode of VZV disease. In 1 patient who suffered from VZV disease just before HSCT, donor-derived VZV IgG was elevated within 3 months after HSCT. On the other hand, 2 patients who received reduced-intensity conditioning (RIC) transplantation from an IgG1m(f) null donor maintained recipient-derived IgG against VZV for more than 1 year, whereas it was decreased within 3 months in 1 recipient who received conventional conditioning. In conclusion, the production of anti-VZV IgG by recipient plasma cells persists long after RIC. In patients without symptomatic VZV reactivation, donor-derived anti-VZV IgG did not reach titers comparable to those measured in healthy virus carriers.

KW - Allogeneic stem cell transplantation

KW - Humoral immunity

KW - Immunoglobulin G allotype

KW - Varicella-Zoster virus

UR - http://www.scopus.com/inward/record.url?scp=84879401283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879401283&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.04.007

DO - 10.1016/j.bbmt.2013.04.007

M3 - Article

C2 - 23583826

AN - SCOPUS:84879401283

VL - 19

SP - 1013

EP - 1020

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -